UroGen Pharma
URGN
139 hedge funds and large institutions have $460M invested in UroGen Pharma in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 45 increasing their positions, 48 reducing their positions, and 18 closing their positions.
216% more call options, than puts
Call options by funds: $1.71M | Put options by funds: $542K
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
19% more capital invested
Capital invested by funds: $386M → $460M (+$73.9M)
4.31% more ownership
Funds ownership: 85.96% → 90.27% (+4.3%)
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
1% more funds holding
Funds holding: 138 → 139 (+1)
6% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 48
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$34.2M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$31.8M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$5.58M |
| 4 |
JP Morgan Chase
New York
|
+$3.73M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
+$3.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$17.6M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.19M |
| 3 |
CF
Cantor Fitzgerald
New York
|
-$2.83M |
| 4 |
Millennium Management
New York
|
-$2.37M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.34M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OC
151
Oppenheimer & Co
New York
| – | -$126K | -11,875 | Closed |
|
152
Lazard Asset Management
New York
| – | -$67.3K | -6,308 | -99% |
|
|
KK
153
KLP Kapitalforvaltning
Oslo,
Norway
| – | -$58.6K | -5,500 | Closed |
|
154
US Bancorp
Minneapolis,
Minnesota
| – | -$501 | -47 | Closed |
|
|
S
155
SignatureFD
Atlanta,
Georgia
| – | -$234 | -22 | Closed |
|
|
CIAM
156
Caitong International Asset Management
Hong Kong
| – | -$149 | -14 | Closed |
|
|
IA
157
IFP Advisors
Tampa,
Florida
| – | -$43 | -4 | Closed |
|
URGN Hedge Fund Activity: Q1 2025 in Review
139 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q1 2025, worth a combined $460M — up 19% from $386M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new URGN positions and 18 closed out — a net gain of 1 holder — while 45 added to existing stakes and 48 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $34.2M. The largest seller was Adage Capital Partners, cutting an estimated $17.6M.
- 139 institutional investors held UroGen Pharma (URGN) as of Q1 2025, up from 138 in Q4 2024.
- Funds reported $460M of UroGen Pharma stock for Q1 2025, up 19% quarter-over-quarter.
- 19 funds opened new UroGen Pharma positions in Q1 2025 and 18 closed out, a net change of +1 holder.
- The largest UroGen Pharma buyer in Q1 2025 was RA Capital Management, an estimated $34.2M added.
- The largest UroGen Pharma seller in Q1 2025 was Adage Capital Partners, an estimated $17.6M sold.
Based on aggregated 13F filings for Q1 2025.